Clinical trial
A Phase 2B/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tazbentetol in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07325591 is registered in ClinicalTrials.gov with Spinogenix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2B/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tazbentetol in Participants With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Spinogenix
- Phase
- Phase 2/3
- Overall status
- Not yet recruiting
- Start date
- October 1, 2026
- Completion date
- March 1, 2028
- Enrollment
- 430 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.